Dr. Robert Alan Nagourney is a distinguished Hematology and Medical Oncology specialist based in Long Beach, California. Graduating with honors in 1979, he brings over four decades of diverse experience to the forefront of cancer treatment and research. Dr. Nagourney is board certified in Internal Medicine, Medical Oncology, and Hematology, holding medical licenses in both California and Virginia.

As the Medical and Laboratory Director of The Nagourney Cancer Institute (formerly Rational Therapeutics) and an Associate Clinical Professor at the University of California, Irvine, he has dedicated his career to pioneering personalized cancer treatment. He is internationally recognized for his groundbreaking work in developing "functional profiling," a method that uses a patient's own living cancer cells to predict how they will respond to treatment before it is administered. He has been a TEDx speaker and has been featured on national and local television such as CNN, ABC World News Tonight, CNBC, Extra, Hard Copy, Fox 11 LA, KTLA 5, ABC7 (Los Angeles) and major newspapers such as the Wall Street Journal, Orange County Register, and Cincinnati Enquirer. He has also been featured internationally, such as on the Australian TV show Good Medicine, and Univision's Primer Impacto.

Among his many accomplishments, as co-investigator on national cooperative trials, Dr. Nagourney is recognized for the introduction of Cisplatin/Gemcitabine doublets in the treatment of advanced ovarian and breast cancers. Dr. Nagourney is author of the book Outliving Cancer, cancer research and treatment blogger, practicing oncologist, and cancer researcher.

Dr. Nagourney has received local awards such as the Trailblazer in Medicine award by the NAACP Long Beach branch and Research Executive of the Year by the Los Angeles Business Journal. He has also served as a reviewer and on the editorial boards of several journals including Clinical Cancer Research, British Journal of Cancer, Gynecologic Oncology, Cancer Research and the Journal of Medicinal Food.

His focus on the laboratory study of "programmed cell death" in cancer cells has provided a robust and reliable method for predicting patient response and improving survival outcomes. This innovative approach is at the core of the EVA-PCD assay, a technology he developed to measure the effectiveness of chemotherapy, targeted agents, and novel drug combinations.

Dr. Nagourney is a prolific author, with over 100 manuscripts, book chapters, and abstracts published in major peer-reviewed journals such as the Journal of Clinical Oncology, Cancer Research, and the British Journal of Cancer. His work continues to shape the future of oncology, moving it away from a one-size-fits-all model to a truly personalized, patient-centered approach.